The Lukan Jerusalem

Luke writes about Jerusalem and the temple much more often than do the other canonical evangelists, as well as in significantly different ways than do Mark, Matthew and John. In this dissertation I have attempted to determine the reason for this distinctly Lukan treatment. The first chapter consists of an introduction to the characteristics of the Jerusalem motif in Luke-Acts, and a survey and evaluation of scholarly treatments of this subject. My discussion with the relevant literature led me to conclude that Jerusalem and the temple are important literary features for Luke, that this importance does not cease at Acts 8:1 as many scholars have claimed, and that this importance is related to the idea of religious authority. In the subsequent chapters I explored each of these observations. The second chapter focuses on what is the Lukan valuation of Jerusalem and the temple. I analyzed Lukan emendations of Markan passages and passages found only in Luke\u27s gospel. The result of this work was the conclusion that Luke presented Jerusalem and the temple as holy space. This is a decidedly more favorable view of Jerusalem and the temple than is found in Mark\u27s gospel. In the third chapter I dealt with the arguments for viewing both Acts 6:8-8:1 and the movement of the narrative following Acts 8:1 as signifying a rejection or replacement of the temple. My conclusion was that these arguments cannot be sustained; rather, both sets of literary features witness to the importance of Jerusalem and the temple for Luke. Finally, chapter four treats the question of the import of Jerusalem and the temple for Luke. It is commonly recognized that in Luke-Acts Jerusalem is the place where the Christian leaders reside. So too, a number of scholars have argued that Luke presents the Christian leaders as the new leaders of Israel. What has not been appreciated is the role of Jerusalem and the temple in the Lukan treatment of the transfer of religious authority. I show how in the narrative Luke presents a struggle for the leadership of the Jewish world with Jerusalem and the temple as the focal points of this struggle. Jerusalem and the temple are important because they represent the place where religious authority my be exercised by both the Jewish and Christian leaders

Mass spectra of sn

Extremely 13C‐depleted sn‐2‐hydroxyarchaeol is widely observed at marine methane seep sites. It is the first biosynthetic product that provides information about a previously unknown microorganism involved in anaerobic methanotrophy, a process that occurs widely in marine sediments. The mono‐ and di‐TMS derivatives of this compound yield sharply differing and distinctive mass spectra. Depending on reaction conditions, either of these products can be formed in the course of conventional analyses

Punishing parents for the crimes of their children

In recent years there has been a profusion of laws that punish parents for their children’s offences. These parental responsibility laws are based on the assumption that parents of children who offend have not accepted their responsibility and that they can be made to do so by the imposition of court orders and financial penalties. In this paper I will examine the efficacy of punishing parents for the crimes of their children. I will consider whether parental responsibility laws are an effective means of tackling youth crime; or should policies that strengthen the family and improve parenting skills be pursued as strategies for preventing juvenile offending behaviour

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

Abstract: Background: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)\u2013defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). Methods: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. Results: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52\u20131.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. Conclusions: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01994720.Abstract: BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with acute ischemic stroke or transient ischemic attack in which the efficacy and safety of ticagrelor were compared with those of aspirin. The main safety objective was assessment of PLATO (Platelet Inhibition and Patient Outcomes)-defined major bleeds on treatment, with special focus on intracranial hemorrhage (ICrH). METHODS: An independent adjudication committee blinded to study treatment classified bleeds according to the PLATO, TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) definitions. The definitions of ICrH and major bleeding excluded cerebral microbleeds and asymptomatic hemorrhagic transformations of cerebral infarctions so that the definitions better discriminated important events in the acute stroke population. RESULTS: A total of 13 130 of 13 199 randomized patients received at least 1 dose of study drug and were included in the safety analysis set. PLATO major bleeds occurred in 31 patients (0.5%) on ticagrelor and 38 patients (0.6%) on aspirin (hazard ratio, 0.83; 95% confidence interval, 0.52-1.34). The most common locations of major bleeds were intracranial and gastrointestinal. ICrH was reported in 12 patients (0.2%) on ticagrelor and 18 patients (0.3%) on aspirin. Thirteen of all 30 ICrHs (4 on ticagrelor and 9 on aspirin) were hemorrhagic strokes, and 4 (2 in each group) were symptomatic hemorrhagic transformations of brain infarctions. The ICrHs were spontaneous in 6 and 13, traumatic in 3 and 3, and procedural in 3 and 2 patients on ticagrelor and aspirin, respectively. In total, 9 fatal bleeds occurred on ticagrelor and 4 on aspirin. The composite of ICrH or fatal bleeding included 15 patients on ticagrelor and 18 on aspirin. Independently of bleeding classification, PLATO, TIMI, or GUSTO, the relative difference between treatments for major/severe bleeds was similar. Nonmajor bleeds were more common on ticagrelor. CONCLUSIONS: Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds. There were few ICrHs